Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
作者： Shigeru Yutani , Kazuomi Ueshima , Kazumichi Abe , Atsushi Ishiguro , Junichi Eguchi
DOI: 10.1155/2015/473909
关键词: Hepatitis C virus 、 Antigen 、 Immunology 、 Hepatitis C 、 Vaccination 、 Hepatocellular carcinoma 、 Hepacivirus 、 Immunoglobulin G 、 Immune system 、 Medicine
摘要: … Uemura et al., “A randomized phase II trial of personalized … cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. … cancer as therapeutic cancer vaccine,” Cancer Immunology, …
hindawi.com
core.ac.uk参考文章(26)
Kazumasa Matsumoto, Masanori Noguchi, Takefumi Satoh, Ken-Ichi Tabata, Tetsuo Fujita, Masatsugu Iwamura, Akira Yamada, Nobukazu Komatsu, Shiro Baba, Kyogo Itoh, A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJUI. ,vol. 108, pp. 831- 838 ,(2011) , 10.1111/J.1464-410X.2010.09933.X
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Ann-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Rongcheng Luo, Jifeng Feng, Shenglong Ye, Tsai-Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jiejun Wang, Won Young Tak, Hongming Pan, Karin Burock, Jessie Zou, Dimitris Voliotis, Zhongzhen Guan, None, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. ,vol. 10, pp. 25- 34 ,(2009) , 10.1016/S1470-2045(08)70285-7
Shigeru Yutani, Nobukazu Komatsu, Shigeki Shichijo, Kazumi Yoshida, Hiroko Takedatsu, Minoru Itou, Ryoko Kuromatu, Tatsuya Ide, Masatoshi Tanaka, Michio Sata, Akira Yamada, Kyogo Itoh, Phase I clinical study of a peptide vaccination for hepatitis C virus‐infected patients with different human leukocyte antigen‐class I‐A alleles Cancer Science. ,vol. 100, pp. 1935- 1942 ,(2009) , 10.1111/J.1349-7006.2009.01256.X
Masanori Noguchi, Tetsuro Sasada, Kyogo Itoh, Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine Cancer Immunology, Immunotherapy. ,vol. 62, pp. 919- 929 ,(2013) , 10.1007/S00262-012-1379-1
Masatoshi Kudo, Hobyung Chung, Seiji Haji, Yukio Osaki, Hiroko Oka, Toshihito Seki, Hiroshi Kasugai, Yo Sasaki, Takashi Matsunaga, Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: the JIS Score Compared With the CLIP Score Hepatology. ,vol. 40, pp. 1396- 1405 ,(2004) , 10.1002/HEP.20486
Shigeru Yutani, Akira Yamada, Kazumi Yoshida, Yukari Takao, Mayumi Tamura, Nobukazu Komatsu, Tatsuya Ide, Masatoshi Tanaka, Michio Sata, Kyogo Itoh, Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. ,vol. 25, pp. 7429- 7435 ,(2007) , 10.1016/J.VACCINE.2007.08.005
Josep M. Llovet, Thomas Decaens, Jean-Luc Raoul, Eveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon-Koo Kang, Eric Assenat, Ho-Yeong Lim, Valerie Boige, Philippe Mathurin, Laetitia Fartoux, Deng-Yn Lin, Jordi Bruix, Ronnie T. Poon, Morris Sherman, Jean-Frédéric Blanc, Richard S. Finn, Won-Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong-Won Park, Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study Journal of Clinical Oncology. ,vol. 31, pp. 3509- 3516 ,(2013) , 10.1200/JCO.2012.47.3009
Jesús Prieto, Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe, Juan José Lasarte, Jose L. Pérez-Gracia, Ignacio Melero, A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology. ,vol. 59, pp. 81- 88 ,(2013) , 10.1016/J.JHEP.2013.02.022
Ryuji Takahashi, Yukinao Ishibashi, Koji Hiraoka, Satoko Matsueda, Kouichirou Kawano, Akihiko Kawahara, Masayoshi Kage, Koichi Ohshima, Ryuya Yamanaka, Shigeki Shichijo, Kazuo Shirouzu, Kyogo Itoh, Tetsuro Sasada, Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Science. ,vol. 104, pp. 1285- 1294 ,(2013) , 10.1111/CAS.12226